Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235905 · ClinicalTrials.gov registry record · Phase 2
Open-Label of SPN-820 in Adults With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Navitor Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06235905 is a Phase 2 study of Major Depressive Disorder that has completed, run by Navitor Pharmaceuticals. The registered enrollment target is 40 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06235905, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Navitor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
Conditions Studied
Interventions
- DRUG NV-5138
Study Locations (1)
California
- Viking Clinical Research - Temecula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2024-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06235905
The ClinicalTrials.gov registry entry for NCT06235905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The listed sponsor is Navitor Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which NV-5138 is the first listed.
NCT06235905 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06235905 about?
NCT06235905 is a clinical study titled "Open-Label of SPN-820 in Adults With Major Depressive Disorder". This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
What is the current status of trial NCT06235905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-15. Estimated completion is 2024-08-18.
What conditions does trial NCT06235905 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06235905?
The interventions under investigation include: NV-5138 (DRUG).
Who is sponsoring clinical trial NCT06235905?
This trial is sponsored by Navitor Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06235905 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.